Sustained durability of responses and improved progression-free and overall survival with imatinib treatment for accelerated phase and blast crisis chronic myeloid leukemia: long-term follow-up of the STI571 0102 and 0109 trials

Podobne zapisy

• High rates of durable response are achieved with imatinib after treatment with interferon α plus cytarabine: results from the International Randomized Study of Interferon and STI571 (IRIS) trial
  od: Guilhot, François, i wsp.
  Wydane: (2009)
• Triptolide induces cell death independent of cellular responses to imatinib in blast crisis CML cells including quiescent CD34(+) primitive progenitor cells
  od: Mak, Duncan H., i wsp.
  Wydane: (2009)
• Homoharringtonine with Imatinib in Chronic, Accelerated, and Blast Phase Chronic Myeloid Leukemia
  od: Maiti, Abhishek, i wsp.
  Wydane: (2017)
• Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS)
  od: Hughes, Timothy P., i wsp.
  Wydane: (2010)
• Management of Skin Toxicity Related to the Use of Imatinib Mesylate (STI571, Glivec™) for Advanced Stage Gastrointestinal Stromal Tumours
  od: Scott, Lucy C., i wsp.
  Wydane: (2005)